AstraZeneca Sues to Block MSN Labs’ Copy of Cancer Drug’s Tablet

Copies of AstraZeneca Plc’s Calquence tablets proposed by MSN Laboratories Pvt. Ltd. infringe two patents for the blood-cancer treatment, according to a federal lawsuit filed six months after MSN settled a case over the blockbuster drug’s capsule formulation.

MSN’s generic version of the tablets, which have a 100-milligram base equivalent of Calquence’s active ingredient, acalabrutinib maleate, infringe US Patent Nos. 10,272,083 and 11,059,829, according to a complaint filed by AstraZeneca and its Acerta Pharma BV unit Jan. 10 in the US District Court for the District of Delaware.

MSN in July became the last generic-drug maker to settle in ...